← FDA DRUG APPROVALS

FDA ANDA · ANDA064061

CEFACLOR

Sponsor: IVAX SUB TEVA PHARMS

APPLICATION
ANDA064061
TYPE
ANDA
ORIGINAL APPROVAL
1995-04-27
LATEST ACTION
1999-08-20
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CEFACLORDiscontinued
CEFACLOR EQ 250MG BASE · CAPSULE · ORAL
CEFACLORDiscontinued
CEFACLOR EQ 500MG BASE · CAPSULE · ORAL

Approval history

1999-08-20Manufacturing (CMC) · Supplement 3AP
1998-12-09Manufacturing (CMC) · Supplement 2AP
1997-05-30Manufacturing (CMC) · Supplement 1AP
1995-04-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →